EXPERT URGES OSTEOPOROSIS PATIENTS TO GET BACK ON TRACK WITH BONE-HEALTH INJECTIONS
Extra precautions taken at Imperial College London Diabetes Centre to protect patients at its reopened facilities
Abu Dhabi, United Arab Emirates. 21 October 2020:
With a focus on safety precautions at all of its recently reopened facilities, Mubadala Healthcare’s Imperial College London Diabetes Centre (ICLDC) is encouraging those patients with osteoporosis who are treated with denosumab to return to their normal injection schedules to ensure optimal bone health and avoid the risk of bone fractures.
Consultant endocrinologist and diabetologist Dr Sara Suliman explains that because advancing age and chronic conditions such as diabetes make people more vulnerable to the effects of COVID-19, many osteoporosis patients were previously encouraged not to leave the house for non-emergency care during the height of the pandemic.
She says: “At ICLDC, we specialize in diabetes and other endocrine diseases so we treat more than 8,000 patients with osteoporosis. Of these, approximately 10 per cent are on Denosumab injections most of whom are already late in having their scheduled denosumab injection, so we have implemented a host of protective measures to allow them to get safely back on schedule.”
While osteoporosis causes bones to weaken and become more susceptible to fractures, treatment with denosumab prevents bone loss by blocking a specific receptor in the body to decrease bone breakdown. However, the treatment is intended to be lifelong and if it is stopped or delayed, bone health decreases rapidly, potentially increasing the risk of fractures significantly after a delay of just two months.
Dr Suliman says: “It is important that these patients receive the injections every six months, or their bone mineral density – meaning the quality and quantity of bone – will deteriorate even more quickly than before treatment, falling to pre-treatment levels within just 12 months.”
She adds that since many of ICLDC’s patients treated with denosumab are older and/or have diabetes, ICLDC is scheduling the vital injection appointments in dedicated areas, interspersed in such a way that patients are not exposed to more people than necessary.
“This approach is on top of the existing hygiene precautions put in place to keep all of our patients and staff as safe as possible,” she explains.
According to the International Osteoporosis Foundation, one in three women and one in five men over 50 will suffer a fracture due to osteoporosis, and many of the risk factors for the disease are prevalent in the UAE.
These risk factors – some of which can be addressed through lifestyle changes – include vitamin D deficiency; low mobility levels; premature menopause; long-term steroid use; smoking; being underweight; bone diseases; malabsorption of nutrients and other dietary issues such as calcium deficiency; and a family history of fractures.
About Imperial College London Diabetes Centre
Imperial College London Diabetes Centre (ICLDC), part of Mubadala’s network of world-class healthcare providers, is a state-of-the-art outpatient facility that specialises in diabetes treatment, research, training and public health awareness. In just over a decade, the Centre has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients to receive the full spectrum of care they need in one place.
With more than 80 diabetes professionals and endocrinologists under one roof, ICLDC offers best-in-class medical attention from first diagnosis to disease management across 11 specialist practice areas including adult and paediatric endocrinology, treatment of metabolic and electrolyte disorders, pre- and post-bariatric surgery care, heart disease prevention, nutritional advice, ophthalmology, nephrology and podiatry.
ICLDC was established in 2006 in Abu Dhabi by Mubadala in partnership with the UK’s Imperial College London to address the growing demand for diabetes care in the UAE. The centre now operates three branches across Abu Dhabi and Al Ain, touching the lives of more than one million people through patient-centric programmes and public health initiatives. In 2007, ICLDC launched Diabetes.Knowledge.Action, now the longest running public health awareness campaign in the country. The initiative promotes an active lifestyle through an ongoing calendar of events for the whole community – Major activations include an annual walkathon that coincides with the World Diabetes Day in November.
ICLDC holds the Joint Commission International (JCI) Clinical Care Program Certification in Outpatient Diabetes Management and JCI Accreditation for Ambulatory Care.
For more information, please visit www.icldc.ae
About Mubadala Investment Company
Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.
Mubadala’s $232 billion (AED 853 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to actively source deals. In the UAE, we are driving sustainable growth by optimizing scale and efficiency, supporting the continued diversification and global integration of the local economy while growing our shareholder value.
Headquartered in Abu Dhabi, Mubadala has offices in London, Rio de Janeiro, Moscow, New York, San Francisco and Beijing.
For more information about Mubadala, please visit: www.mubadala.com